Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
norovirus bivalent vlp vaccine
- Development stage
- Unknown
- Lead developer
- HilleVax
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The norovirus bivalent VLP vaccine is an intramuscularly administered vaccine designed to prevent gastroenteritis caused by norovirus. It is a bivalent virus-like particle (VLP) vaccine, meaning it contains two different types of norovirus VLPs. The vaccine is adjuvanted with Monophosphoryl lipid A (MPL) and Aluminum Hydroxide (Al(OH)3) to enhance the immune response. It aims to induce post-vaccination serum antibody responses, increase the number of antibody-secreting cells, and stimulate memory B-cell responses directed against norovirus antigens.
- Other names
- IM Norovirus Bivalent VLP Vaccine
02
Targets
Norovirus VP1
Beyond the preview
Go deeper on norovirus bivalent vlp vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on norovirus bivalent vlp vaccine.